HC Wainwright Comments on AEON Biopharma Q3 Earnings

AEON Biopharma, Inc. (NASDAQ:AEON) – Equities research analysts at HC Wainwright issued their Q3 2026 EPS estimates for AEON Biopharma in a research report issued to clients and investors on Friday, August 14th. HC Wainwright analyst D. Tsao expects that the company will earn ($0.07) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $1.20 target price on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($0.77) per share. HC Wainwright also issued estimates for AEON Biopharma’s Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS and Q4 2027 earnings at ($0.06) EPS.

AEON has been the subject of several other reports. Zacks Research raised AEON Biopharma to a “hold” rating in a research note on Wednesday, May 27th. Lake Street Capital assumed coverage on AEON Biopharma in a research note on Thursday, July 30th. They issued a “buy” rating and a $1.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1.10.

AEON Biopharma Stock Down 7.1%

Shares of AEON stock opened at $0.26 on Monday. The stock has a market capitalization of $6.46 million, a PE ratio of 1.42 and a beta of 0.65. AEON Biopharma has a 52-week low of $0.22 and a 52-week high of $1.45. The stock’s 50-day moving average price is $0.47 and its 200 day moving average price is $0.81.

Institutional Trading of AEON Biopharma

An institutional investor recently raised its position in AEON Biopharma stock. Geode Capital Management LLC grew its position in AEON Biopharma, Inc. (NASDAQ:AEON) by 27.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,134 shares of the company’s stock after acquiring an additional 13,061 shares during the period. Geode Capital Management LLC owned about 0.51% of AEON Biopharma worth $66,000 at the end of the most recent quarter. Institutional investors own 22.78% of the company’s stock.

AEON Biopharma Company Profile

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.